Amenamevir

From Wikipedia, the free encyclopedia
Amenamevir
Amenamevir.svg
Clinical data
Trade namesAmenalief
Other namesASP-2151, ASP2151
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • N-(2,6-Dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC24H26N4O5S
Molar mass482.56 g·mol−1
3D model (JSmol)
  • Cc1cccc(C)c1N(CC(=O)Nc1ccc(-c2ncon2)cc1)C(=O)C1CCS(=O)(=O)CC1
  • InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29)
  • Key:MNHNIVNAFBSLLX-UHFFFAOYSA-N

Amenamevir (trade name Amenalief) is an antiviral drug used for the treatment of shingles (herpes zoster).

It acts as an inhibitor of the zoster virus's helicase–primase complex.[1][2]Amenamevir was approved in Japan for the treatment of shingles in 2017.[3]

References[edit]

  1. ^ Kawashima M, Nemoto O, Honda M, Watanabe D, Nakayama J, Imafuku S, et al. (November 2017). "Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study". The Journal of Dermatology. 44 (11): 1219–1227. doi:10.1111/1346-8138.13948. PMC 5697646. PMID 28681394.
  2. ^ Yajima M, Yamada H, Takemoto M, Daikoku T, Yoshida Y, Long T, et al. (March 2017). "Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor". Antiviral Research. 139: 95–101. doi:10.1016/j.antiviral.2016.12.008. PMID 28027917. S2CID 43813287.
  3. ^ "Maruho Receives Manufacturing and Marketing Approval for Anti-Herpes Virus Agent "Amenalief® Tab. 200mg" in Japan" (Press release). evaluategroup.com. July 3, 2017.